| ［1］ |
Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020： Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries ［J］. CA Cancer J Clin，2021，71（3）： 209-249.
|
| ［2］ |
Jiang YZ，Ma D，Suo C，et al. Genomic and transcriptomic landscape of triple-negative breast cancers：subtypes and treatment strategies ［J］. Cancer Cell，2019，35（3）：428-440. e5.
|
| ［3］ |
Medina MA，Oza G，Sharma A，et al. Triple-negative breast cancer： a review of conventional and advanced therapeutic strategies ［J］. Int J Environ Res Public Health，2020，17（6）：2078.
|
| ［4］ |
Siegel RL，Miller KD，Fuchs HE，et al. Cancer statistics，2021 ［J］. CA Cancer J Clin，2021，71（1）： 7-33.
|
| ［5］ |
Liao Y，Gui Y，Li Q，et al. The signaling pathways and targets of natural products from traditional Chinese medicine treating gastric cancer provide new candidate therapeutic strategies ［J］. Biochim Biophys Acta Rev Cancer，2023，1878（6）：188998.
|
| ［6］ |
Xiu LJ，Sun DZ，Jiao JP，et al. Anticancer effects of traditional Chinese herbs with phlegm-eliminating properties-an overview ［J］. J Ethnopharmacol，2015，172：155-161.
|
| ［7］ |
Lee YW，Chen TL，Shih YR，et al. Adjunctive traditional Chinese medicine therapy improves survival in patients with advanced breast cancer：a population-based study ［J］. Cancer，2014，120（9）：1338-1344.
|
| ［8］ |
Ateba SB，Mvondo MA，Ngeu ST，et al. Natural terpenoids against female breast cancer：a 5-year recent research ［J］. Curr Med Chem，2018，25（27）：3162-3213.
|
| ［9］ |
Liu Z，Ma L，Zhou GB. The main anticancer bullets of the Chinese medicinal herb，thunder god vine ［J］. Molecules，2011，16（6）：5283-5297.
|
| ［10］ |
Kupchan SM，Court WA，Dailey RG Jr，et al. Triptolide and tripdiolide，novel antileukemic diterpenoid triepoxides from tripterygium wilfordii ［J］. J Am Chem Soc，1972，94（20）：7194-7195.
|
| ［11］ |
Li XJ，Jiang ZZ，Zhang LY. Triptolide：progress on research in pharmacodynamics and toxicology ［J］. J Ethnopharmacol，2014，155（1）：67-79.
|
| ［12］ |
Wang C，Dai S，Zhao X，et al. Celastrol as an emerging anticancer agent：current status，challenges and therapeutic strategies ［J］. Biomed Pharmacother，2023，163：114882.
|
| ［13］ |
Jang SY，Jang SW，Ko J. Celastrol inhibits the growth of estrogen positive human breast cancer cells through modulation of estrogen receptor α ［J］. Cancer Lett，2011，300（1）：57-65.
|
| ［14］ |
Yang B，Zhang B，Cao Z，et al. The lipogenic LXR-SREBF1 signaling pathway controls cancer cell DNA repair and apoptosis and is a vulnerable point of malignant tumors for cancer therapy ［J］. Cell Death Differ，2020，27（8）：2433-2450.
|
| ［15］ |
Gao B，Chen J，Han B，et al. Identification of triptonide as a therapeutic agent for triple negative breast cancer treatment ［J］. Sci Rep，2021，11（1）：2408.
|
| ［16］ |
郭少贤，李亚杰，吕博杰，等. 雷公藤联合吉西他滨治疗中晚期胰腺癌的临床效果及安全性分析 ［J］. 中国中西医结合消化杂志，2020，28（02）：99-103.
|
| ［17］ |
Thompson D，Easton DF. Cancer incidence in BRCA1 mutation carriers ［J］. J Natl Cancer Inst，2002，94（18）：1358-1365.
|
| ［18］ |
Kiwerska K，Szyfter K. DNA repair in cancer initiation，progression，and therapy-a double-edged sword ［J］. J Appl Genet，2019，60（3/4）：329-334.
|
| ［19］ |
London RE. The structural basis of XRCC1-mediated DNA repair ［J］. DNA Repair （Amst），2015，30：90-103.
|
| ［20］ |
Rouleau M，Patel A，Hendzel MJ，et al. PARP inhibition：PARP1 and beyond ［J］. Nat Rev Cancer，2010，10（4）：293-301.
|
| ［21］ |
Gibson BA，Kraus WL. New insights into the molecular and cellular functions of poly （ADP-ribose） and PARPs ［J］. Nat Rev Mol Cell Biol，2012，13（7）：411-424.
|
| ［22］ |
Sarasin A，Kauffmann A. Overexpression of DNA repair genes is associated with metastasis：a new hypothesis ［J］. Mutat Res，2008，659（1-2）：49-55.
|
| ［23］ |
Kou Y，Koag MC，Lee S. Structural and kinetic studies of the effect of guanine N7 alkylation and metal cofactors on DNA replication ［J］. Biochemistry，2018，57（34）：5105-5116.
|
| ［24］ |
Kothandapani A，Sawant A，Dangeti VS，et al. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity ［J］. Nucleic Acids Res，2013，41（15）：7332-7343.
|
| ［25］ |
Zhang Z，Sun C，Zhang L，et al. Triptolide interferes with XRCC1/PARP1-mediated DNA repair and confers sensitization of triple-negative breast cancer cells to cisplatin ［J］. Biomed Pharmacother，2019，109：1541-1546.
|
| ［26］ |
Taher MY，Davies DM，Maher J. The role of the interleukin （IL）-6/IL-6 receptor axis in cancer ［J］. Biochem Soc Trans，2018，46（6）：1449-1462.
|
| ［27］ |
Jayatilaka H，Tyle P，Chen JJ，et al. Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration ［J］. Nat Commun，2017，8：15584.
|
| ［28］ |
Knüpfer H，Preiss R. Significance of interleukin-6 （IL-6） in breast cancer （review） ［J］. Breast Cancer Res Treat，2007，102（2）：129-135.
|
| ［29］ |
Fu S，Lin J. Blocking interleukin-6 and interleukin-8 signaling inhibits cell viability，colony-forming activity，and cell migration in human triple-negative breast cancer and pancreatic cancer cells ［J］. Anticancer Res，2018，38（11）：6271-6279.
|
| ［30］ |
Giridharan S，Srinivasan M. Mechanisms of NF-κB p65 and strategies for therapeutic manipulation ［J］. J Inflamm Res，2018，11：407-419.
|
| ［31］ |
Mulero MC，Huxford T，Ghosh G. NF-κB，IκB，and IKK：integral components of immune system signaling ［J］. Adv Exp Med Biol，2019，1172：207-226.
|
| ［32］ |
Okamoto M，Mizukami Y. Gper negatively regulates TNFα-induced IL-6 production in human breast cancer cells via NF-κB pathway ［J］. Endocr J，2016，63（5）：485-493.
|
| ［33］ |
Liang S，Chen Z，Jiang G，et al. Activation of gper suppresses migration and angiogenesis of triple negative breast cancer via inhibition of NF-κB/IL-6 signals ［J］. Cancer Lett，2017，386：12-23.
|
| ［34］ |
Yan F，Wu Z，Li Z，et al. Celastrol inhibits migration and invasion of triple-negative breast cancer cells by suppressing interleukin-6 via downregulating nuclear factor-κB （NF-κB） ［J］. Med Sci Monit，2020，26：e922814.
|
| ［35］ |
Pines J，Hunter T. Isolation of a human cyclin cDNA：evidence for cyclin mrna and protein regulation in the cell cycle and for interaction with p34cdc2 ［J］. Cell，1989，58（5）：833-846.
|
| ［36］ |
Fung TK，Poon RY. A roller coaster ride with the mitotic cyclins ［J］. Semin Cell Dev Biol，2005，16（3）：335-342.
|
| ［37］ |
Peters JM. The anaphase promoting complex/cyclosome：a machine designed to destroy ［J］. Nat Rev Mol Cell Biol，2006，7（9）：644-656.
|
| ［38］ |
冯立文，虞飞，李姝，等. P53、p21waf-1和cdk1在乳腺癌组织中的表达及意义 ［J］. 诊断病理学杂志，2019，26（8）：516-518.
|
| ［39］ |
Matsushime H，Roussel MF，Ashmun RA，et al. Colony-stimulating factor 1 regulates novel cyclins during the G1 phase of the cell cycle ［J］. Cell，1991，65（4）：701-713.
|
| ［40］ |
Spring LM，Wander SA，Zangardi M，et al. CDK 4/6 inhibitors in breast cancer：current controversies and future directions ［J］. Curr Oncol Rep，2019，21（3）：25.
|
| ［41］ |
Peng B，Xu L，Cao F，et al. HSP90 inhibitor，celastrol，arrests human monocytic leukemia cell U937 at G0/G1 in thiol-containing agents reversible way ［J］. Mol Cancer，2010，9：79.
|
| ［42］ |
Mishra SJ，Khandelwal A，Banerjee M，et al. Selective inhibition of the Hsp90α isoform ［J］. Angew Chem Int Ed Engl，2021，60（19）：10547-10551.
|
| ［43］ |
Lee AS. Glucose-regulated proteins in cancer：molecular mechanisms and therapeutic potential ［J］. Nat Rev Cancer，2014，14（4）：263-276.
|
| ［44］ |
Rozpedek W，Pytel D，Mucha B，et al. The role of the PERK/eIF2α/ATF4/CHOP signaling pathway in tumor progression during endoplasmic reticulum stress ［J］. Curr Mol Med，2016，16（6）：533-544.
|
| ［45］ |
Patel PD，Yan P，Seidler PM，et al. Paralog-selective Hsp90 inhibitors define tumor-specific regulation of HER2 ［J］. Nat Chem Biol，2013，9（11）：677-684.
|
| ［46］ |
Li X，Sun L，Hou J，et al. Cell membrane gp96 facilitates HER2 dimerization and serves as a novel target in breast cancer ［J］. Int J Cancer，2015，137（3）：512-524.
|
| ［47］ |
Hodorova I，Rybarova S，Solar P，et al. Gp96 and its different expression in breast carcinomas ［J］. Neoplasma，2008，55（1）：31-35.
|
| ［48］ |
Smid M，Wang Y，Zhang Y，et al. Subtypes of breast cancer show preferential site of relapse ［J］. Cancer Res，2008，68（9）：3108-3114.
|
| ［49］ |
Duan X，Iwanowycz S，Ngoi S，et al. Molecular chaperone GRP94/GP96 in cancers：oncogenesis and therapeutic target ［J］. Front Oncol，2021，11：629846.
|
| ［50］ |
Békés M，Langley DR，Crews CM. Protac targeted protein degraders：the past is prologue ［J］. Nat Rev Drug Discov，2022，21（3）：181-200.
|
| ［51］ |
Gan X，Wang F，Luo J，et al. Proteolysis targeting chimeras （protacs） based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment ［J］. Eur J Pharm Sci，2024，192：106624.
|
| ［52］ |
Qu J，Li J，Zhang Y，et al. AKR1B10 promotes breast cancer cell proliferation and migration via the PI3K/AKT/NF-κB signaling pathway ［J］. Cell Biosci，2021，11（1）：163.
|
| ［53］ |
Lee KL，Chen G，Chen TY，et al. Effects of cancer stem cells in triple-negative breast cancer and brain metastasis：challenges and solutions ［J］. Cancers （Basel），2020，12（8）.
|
| ［54］ |
Zhang D，Sun B，Zhao X，et al. Twist1 accelerates tumour vasculogenic mimicry by inhibiting claudin15 expression in triple-negative breast cancer ［J］. J Cell Mol Med，2020，24（13）：7163-7174.
|
| ［55］ |
Deepak KGK，Vempati R，Nagaraju GP，et al. Tumor microenvironment：challenges and opportunities in targeting metastasis of triple negative breast cancer ［J］. Pharmacol Res，2020，153：104683.
|
| ［56］ |
Rueda OM，Sammut SJ，Seoane JA，et al. Dynamics of breast-cancer relapse reveal late-recurring er-positive genomic subgroups ［J］. Nature，2019，567（7748）：399-404.
|
| ［57］ |
Devanand P，Sundaramoorthy S，Ryu MS，et al. Translational downregulation of Twist1 expression by antiproliferative gene，B-cell translocation gene 2，in the triple negative breast cancer cells ［J］. Cell Death Dis，2019，10（6）：410.
|
| ［58］ |
Hata T，Rajabi H，Yamamoto M，et al. Targeting MUC1-C inhibits TWIST1 signaling in triple-negative breast cancer ［J］. Mol Cancer Ther，2019，18（10）：1744-1754.
|
| ［59］ |
Wang SC，Sun HL，Hsu YH，et al. α-Linolenic acid inhibits the migration of human triple-negative breast cancer cells by attenuating Twist1 expression and suppressing Twist1-mediated epithelial-mesenchymal transition ［J］. Biochem Pharmacol，2020，180：114152.
|
| ［60］ |
Giuli MV，Giuliani E，Screpanti I，et al. Notch signaling activation as a hallmark for triple-negative breast cancer subtype ［J］. J Oncol，2019，2019：8707053.
|
| ［61］ |
Zhong Y，Shen S，Zhou Y，et al. Notch1 is a poor prognostic factor for breast cancer and is associated with breast cancer stem cells ［J］. Onco Targets Ther，2016，9：6865-6871.
|
| ［62］ |
Valcourt DM，Dang MN，Scully MA，et al. Nanoparticle-mediated co-delivery of Notch-1 antibodies and ABT-737 as a potent treatment strategy for triple-negative breast cancer ［J］. ACS Nano，2020，14（3）：3378-3388.
|
| ［63］ |
Garrido-Castro AC，Spurr LF，Hughes ME，et al. Genomic characterization of de novo metastatic breast cancer ［J］. Clin Cancer Res，2021，27（4）：1105-1118.
|
| ［64］ |
Zhang M，Meng M，Liu Y，et al. Triptonide effectively inhibits triple-negative breast cancer metastasis through concurrent degradation of Twist1 and Notch1 oncoproteins ［J］. Breast Cancer Res，2021，23（1）：116.
|
| ［65］ |
Shao H，Ma J，Guo T，et al. Triptolide induces apoptosis of breast cancer cells via a mechanism associated with the WNT/β-catenin signaling pathway ［J］. Exp Ther Med，2014，8（2）：505-508.
|
| ［66］ |
Ou CC，Chen YW，Hsu SC，et al. Triptolide transcriptionally represses HER2 in ovarian cancer cells by targeting NF-κB ［J］. Evid Based Complement Alternat Med，2012，2012：350239.
|